Description

Ulcavis (bismuth subcitrate) Coated Tablets 120 mg. №28

Ingredients:

Each coated tablet contains 120 mg of bismuth subcitrate.

Dosage:

The recommended dosage is one tablet to be taken orally three times a day, preferably after meals.

Indications:

Ulcavis tablets are indicated for the treatment of peptic ulcers and Helicobacter pylori infection.

Contraindications:

Do not use Ulcavis tablets if you are allergic to bismuth subcitrate or any other ingredients in the formulation.

Directions:

Swallow the tablet whole with water. Do not crush or chew the tablet.

Scientific Evidence:

Bismuth subcitrate, the active ingredient in Ulcavis tablets, has been extensively studied for its efficacy in treating peptic ulcers and Helicobacter pylori infection. Research studies have shown that bismuth subcitrate exerts its therapeutic effects by inhibiting the growth of Helicobacter pylori bacteria in the stomach, thereby helping to heal ulcers and prevent their recurrence.

Additional Information:

Ulcavis tablets have been found to be well-tolerated with minimal side effects, making them a preferred choice for the treatment of peptic ulcers. It is important to follow the prescribed dosage and duration of treatment to achieve optimal results. Consult your healthcare provider for personalized advice on the use of Ulcavis tablets.

Studies have also highlighted the role of bismuth subcitrate in reducing the risk of antibiotic resistance when used in combination therapy for Helicobacter pylori eradication. This underscores the importance of bismuth-containing regimens in the management of gastrointestinal disorders.